Your browser doesn't support javascript.
loading
Rapid Efficacy of riSankizumab in pretibial psoriasis invOLVEment: RESOLVE.
Bernardini, Nicoletta; Skroza, Nevena; Atzori, Laura; Mugheddu, Cristina; Megna, Matteo; Cacciapuoti, Sara; Ortoncelli, Michela; Montesu, Maria A; Carpentieri, Antonio; Carriero, Martino; Atzori, Maria G; Addis, Gianmario; Balestri, Riccardo; Rech, Giulia; Bruni, Pierluigi; Papini, Manuela; Potenza, Concetta.
Affiliation
  • Bernardini N; Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy.
  • Skroza N; Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy.
  • Atzori L; Department Medical Sciences and Public Health, University of Cagliari, Italy.
  • Mugheddu C; Department Medical Sciences and Public Health, University of Cagliari, Italy.
  • Megna M; Section of Dermatology, University of Naples Federico II, Naples, Italy.
  • Cacciapuoti S; Section of Dermatology, University of Naples Federico II, Naples, Italy.
  • Ortoncelli M; Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.
  • Montesu MA; Department of Medicine, Surgery and Pharmacy, University of Sassari, Italy.
  • Carpentieri A; Psoriasis Center, Hospital of Brindisi "A. Perrino", Italy.
  • Carriero M; Dermatology Outpatient, ASL Taranto, Italy.
  • Atzori MG; Dermatology Unit, San Francesco Hospital, Nuoro, Italy.
  • Addis G; Dermatology Unit, San Francesco Hospital, Nuoro, Italy.
  • Balestri R; Division of Dermatology, Psoriasis Outpatient Service, Trento, Italy.
  • Rech G; Division of Dermatology, Psoriasis Outpatient Service, Trento, Italy.
  • Bruni P; Department of Medicine and Surgery, Dermatological Clinic of Terni, University of Perugia, Italy.
  • Papini M; Department of Medicine and Surgery, Dermatological Clinic of Terni, University of Perugia, Italy.
  • Potenza C; Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", Sapienza University of Rome, Polo Pontino, Italy.
Drugs Context ; 132024.
Article in En | MEDLINE | ID: mdl-39263599
ABSTRACT

Background:

Despite extraordinary improvements in the management of psoriasis in recent times, some areas of the body, such as the pretibial area, still show an unsatisfactory response and a more significant impact on patient quality of life. This multicentre study focuses on psoriasis affecting sensitive areas (particularly the pretibial area), its impact on quality of life and the therapeutic response to risankizumab.

Methods:

This multicentre prospective observational study recruited patients with moderate-to-severe psoriasis with pretibial area involvement. All patients underwent treatment with risankizumab (150 mg every 3 weeks), and efficacy was assessed after 24 weeks.

Results:

The study included 128 patients with a mean age of 51 years, suffering from moderate-to-severe psoriasis with involvement of the pretibial area with median total Psoriasis Area Severity Index score of 17.05 and Dermatology Life Quality Index of 16.27. The group was further divided into two sub-groups the 'mother patch' group, in whom the very first psoriatic plaque appeared in the pretibial region (45 patients), and the 'non-mother patch' group, in whom the psoriatic lesion in the pretibial region was present but not as the first manifestation (83 patients). In order to better assess the involvement of psoriasis in the pretibial area, the pretibial plaque lesion severity index was also calculated at baseline in all patients extent 2.75, erythema 2.64, infiltration 2.45 and desquamation 2.38. All participants in this study showed a good therapeutic response, with a reduction in all scores.

Conclusions:

The pretibial area is becoming an object of therapeutic interest due to some resistance to clearance and the consequent impairment of patient quality of life. This study showed that risankizumab can give favourable therapeutic results not only in patients with moderate-to-severe psoriasis with involvement of the difficult-to-treat areas but particularly in patients with recalcitrant plaques in the pretibial area.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Drugs Context Year: 2024 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Drugs Context Year: 2024 Document type: Article Affiliation country: Country of publication: